Your web browser is out of date.

For your security and improved experience online, please update your browser.
Update your browser

Diabetes on the Net is intended for healthcare professionals

back to main site

In association with

Time in range
Is this the new gold standard?

Exploring the role of technology and modern insulins for improving glycaemic control in diabetes

*CGM-based targets for adults with type 1 and type 2 diabetes who are not pregnant, not older, or at risk
†Readings >13.9 mmol/L are also included
‡Readings <3.0 mmol/L are also included
This visual was adapted from Battelino T et al (2019) Diabetes Care 42:1593–603

Watch the video

This promotional resource is organised and funded by Novo Nordisk and Abbott.
Marketing and organisational support has been provided by OmniaMed Communications.
The information presented is intended for UK-based healthcare professionals.
Adverse event reporting information and prescribing Information will be available on this website.

Time in range
Is this the new gold standard?

Developments in modern insulins and improvements in flash glucose monitoring technology in diabetes have improved the time that glucose levels remain within target range.

This on demand video features a clinical discussion hosted by Dr Fiona Campbell,  Consultant Paediatrician and Diabetologist and Prof Ramzi Ajjan, Professor of Metabolic Medicine both based at The Leeds Teaching Hospitals NHS Trust. They will explore how technology can facilitate the use of modern insulins to improve glycaemic control and discuss how devices and medicine can be combined to improve the quality of life for individuals with diabetes.

Speakers

Dr Fiona Campbell

Consultant Paediatrician and Diabetologist,
The Leeds Teaching Hospitals NHS Trust
Fiona Campbell has been a Consultant in Paediatric Diabetes for 24 years. She is Associate Medical Director at Leeds Teaching Hospitals NHS Trust, responsible for Children and Young People’s Services, and Trust-wide Clinical Lead for Transition. Clinically, Dr Campbell leads a large diabetes service at Leeds Children’s Hospital, Leeds, caring for patients aged between 0 and 20 years. She has been Chair of the National Children and Young Peoples Diabetes Network in England and Wales, and a member of the National Paediatric Diabetes Audit Project Board for the last 7 years. Internationally, Dr Campbell is a member of the International Society for Paediatric and Adolescent Diabetes and is currently serving her second 3-year term of office on the Council of Healthcare Professionals at Diabetes UK, ensuring that the interests of children and young people living with diabetes are addressed. Most recently Dr Campbell has taken on the role of Diabetes Officer at British Society of Paediatric Endocrinology and Diabetes.

Prof Ramzi Ajjan

Professor of Metabolic Medicine,
The Leeds Teaching Hospitals NHS Trust

Ramzi Ajjan is Professor of Metabolic Medicine and Honorary Consultant in Diabetes and Endocrinology at Leeds University and Leeds Teaching Hospitals Trust. He obtained his PhD from the University of Sheffield and completed his clinical training in Diabetes and Endocrinology at Leeds Teaching Hospitals. He runs a programme of basic, translational and clinical research studies with the collective aim of reducing vascular complications and improving quality of life in individuals with diabetes. He has authored over 150 publications including original articles, reviews and book chapters. His clinical practice concentrates on young adults with diabetes and older individuals at high risk of vascular disease.
He is local research and development lead for Diabetes/Endocrinology and regional clinical research network co-lead for diabetes, endocrine and metabolic conditions. He is deputy Chair of the Clinical Study Group 2 at Diabetes UK, Associate Editor of Diabetes and Vascular Disease Research and member of the editorial board of International Journal of Molecular Sciences.

Video

Play Video

Lorem ipsum dolor sit amet

Lorem ipsum dolor sit amet

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam

Play Video

Lorem ipsum dolor sit amet

Lorem ipsum dolor sit amet

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam

Play Video
Prescribing information for Fiasp®▼ (insulin aspart) can be found here.
Prescribing information for Tresiba® (insulin degludec) can be found here.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Novo Nordisk Limited (Telephone Novo Nordisk Customer Care Centre 0845 6005055). Calls may be monitored for training purposes.

Job code: UK21DI00015; ADC-31344 v1.0. Date of preparation: February 2021

get the latest news

subscribe now

© Copyright OmniaMed Communications. All Rights Reserved

Practical experiences from running an adeno-associated virus gene therapy trials: The Principal Investigator’s perspective

XX September 2020

Complete the registration form

XX Month 2020

Complete the registration form

We use cookies to ensure that we give you the best experience on our website. Some may have been set already. If you continue without changing your settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies. If you have any concerns about this, please click here to find out more.

Confirm
* Mandatory Field
Your data is being collected by OmniaMed Communications on behalf of Novo Nordisk solely for the purpose of processing your registration. Your details will not be shared with any parties other than OmniaMed Communications and Novo Nordisk.